RPI ID: 2021-049-201

Innovation Summary:
A nasal spray formulation combines pentosan polysulfate and mucopolysaccharide polysulfate to prevent and treat COVID-19. The compounds act as viral entry inhibitors by blocking spike protein binding to host cells. The spray is designed for prophylactic and therapeutic use, with potential for broad-spectrum antiviral activity. It is administered intranasally for localized action.

Challenges / Opportunities:
Respiratory viruses like SARS-CoV-2 require effective barrier-based interventions. This invention offers a non-invasive, locally acting solution that can be used in high-risk environments. It supports rapid deployment and self-administration. The formulation may be adapted for other respiratory pathogens.

Key Benefits / Advantages:
✔ Intranasal antiviral delivery
✔ Spike protein inhibition
✔ Prophylactic and therapeutic use
✔ Non-invasive administration
✔ Broad-spectrum potential

Applications:
• COVID-19 prevention
• Respiratory virus treatment
• Public health interventions

Keywords:
#nasalspray #covid19 #antiviraltherapy #pentosanpolysulfate #mucopolysaccharide #respiratoryhealth

Intellectual Property:
US Application 18/237624 US20240066051A1 filed 24-Aug-2023